CytomX Therapeutics (CTMX) Revenue Growth (3y) (2017 - 2026)
CytomX Therapeutics (CTMX) Revenue Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | 79.44% |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 54.05% |
| 10 | CytomX Therapeutics | 603.61 Mn | 256.91 Mn | - | -24.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.14% |
| Dec 31, 2025 | -67.94% |
| Sep 30, 2025 | -18.82% |
| Jun 30, 2025 | 13.23% |
| Mar 31, 2025 | 77.92% |
| Dec 31, 2024 | 50.69% |
| Sep 30, 2024 | 53.80% |
| Jun 30, 2024 | 41.87% |
| Mar 31, 2024 | 71.66% |
| Dec 31, 2023 | 55.49% |
| Sep 30, 2023 | 52.32% |
| Jun 30, 2023 | 52.38% |
| Mar 31, 2023 | -20.57% |
| Dec 31, 2022 | 34.45% |
| Sep 30, 2022 | 1.34% |
| Jun 30, 2022 | 12.56% |
| Mar 31, 2022 | -20.66% |
| Dec 31, 2021 | -0.99% |
| Sep 30, 2021 | -9.77% |
| Jun 30, 2021 | -3.87% |